Adenine Base Editing Corrects IVS4+919 Mutation Linked to Cardiac-Type Fabry Disease

Researchers have developed a novel method to address a cryptic splice mutation linked to cardiac-type Fabry disease, according to findings published in the journal *Gene Therapy*. The study highlights the use of adenine base editing (ABE) to correct the pathogenic G>A mutation at the IVS4+919 site, which is associated with this genetic condition. This approach represents a significant step forward in genetic medicine, offering potential for targeted correction of specific mutations.

The research focuses on utilizing ABE technology, which enables precise editing of single DNA bases without introducing double-strand breaks. By targeting the IVS4+919 mutation, scientists successfully demonstrated the ability to restore normal splicing and gene function in affected cells. The study underscores the potential of base editing as a therapeutic tool for addressing genetic disorders caused by similar mutations. Further investigation will be required to evaluate its safety and efficacy in clinical applications.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 18, 2026

Author

GOAI